Cure Pharmaceutical, a disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, nutraceutical and medical foods markets, has launched a research collaboration with CannaKids.
The collaboration is to develop and research the delivery of various forms and components of cannabinoid molecules for both human and animal therapeutic use, using Cure's patented drug delivery technology.
Multiple human and animal studies have shown that endocannabinoids may play a key role in metabolic processes, lipolysis, pain, gastrointestinal and cancer.
Rob Davidson, CEO of Cure, said:
“The demand for cannabinoid therapeutics has gained momentum. We have created an entire division of the company dedicated to the discovery and development of cannabinoid drug molecules.”
Clinically proven and NCEs are integrated into our CureFilm and other delivery technologies.
“These clinically proven and New Chemical Entities are integrated into our CureFilm and other delivery technologies,” he added.
“Some of these drugs will be repurposed for new indications, delivered through alternate routes, designed as prodrugs and combined with other drugs.”
“Through the use of our delivery technologies, we can titer the accurate dosage for optimal effectiveness.”
Cure will optimise plant base cannabinoids by vertically integrating drug discovery, extraction technology, genetic-specific cannabinoids research, and drug development.
“Cure's strategy is to bring new cannabinoid molecules to the market through the FDA regulatory approval process,” said Ed Maliski, Chief Scientific Officer.
“We will do this while utilising our delivery technologies to increase efficacy. as well as widening the overall therapeutic index.”
Oral thin film formulation is a logical application for cannabis-derived products.
Both Cure and CannaKids will including drug formulations, delivery platforms and manufacturing processes, as well as participating in the research of new technologies and formulations for cannabinoid-therapeutic based products for a variety of indications.
“Oral thin film formulation is a logical application for cannabis-derived products,” said Tracy Ryan, CEO of Cannakids.
“Cure's experience and reputation for scientific integrity, efficiency and purity of its internal formulation and manufacturing processes, make them an ideal partner in this venture to bring pharmaceutical-based cannabinoid therapeutics to the market.”